Paper11057778
'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.
Cervenákov I and 4 others. Int Urol Nephrol, 2000. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate. Papers, record 11057778. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11057778
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Androgen Antagonists | Major topic |
| Cyproterone Acetate | Major topic |
| Hot Flashes | Major topic |
| Orchiectomy | Major topic |
| Prostatectomy | Major topic |
| Prostatic Neoplasms | Major topic |
| Aged | |
| Aged, 80 and over | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7688656 | Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. | Cancer | 1993 | https://conductscience.org/library/papers/7688656 | PubMed |
| 2 | 8201642 | A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate. | J Urol | 1994 | https://conductscience.org/library/papers/8201642 | PubMed |
| 3 | 8821690 | A prospective, randomised study to compare goserelin acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma. | Eur Urol | 1996 | https://conductscience.org/library/papers/8821690 | PubMed |
| 4 | 8536770 | Advances and trends in hormonal therapy for advanced prostate cancer. | Eur Urol | 1995 | https://conductscience.org/library/papers/8536770 | PubMed |
| 5 | 8197933 | Androcur 50 in the treatment of prostatic carcinoma. Belgian multicentric study with the participation of 30 urologists. | Acta Urol Belg | 1994 | https://conductscience.org/library/papers/8197933 | PubMed |
| 6 | 8308973 | Transdermal clonidine for ameliorating post-orchiectomy hot flashes. | J Urol | 1994 | https://conductscience.org/library/papers/8308973 | PubMed |
| 7 | 7528960 | [Hot flashes after orchiectomy in treatment of prostate cancer-- a serious side effect]. | Z Gerontol | 1994 | https://conductscience.org/library/papers/7528960 | PubMed |
| 8 | 7919640 | Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. | Drugs Aging | 1994 | https://conductscience.org/library/papers/7919640 | PubMed |
| 9 | 48206 | Physiologic basis for hormonal theapy in carcinoma of the prostate. | Urol Clin North Am | 1975 | https://conductscience.org/library/papers/48206 | PubMed |
| 10 | 9549167 | [Therapy of vasomotor syndrome in the treatment of advanced prostatic cancer: apropos of 37 cases]. | Arch Ital Urol Androl | 1998 | https://conductscience.org/library/papers/9549167 | PubMed |
| 11 | 9519356 | Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group. | Eur Urol | 1998 | https://conductscience.org/library/papers/9519356 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 16985883 | Adverse events associated with hormonal therapy for prostate cancer. | Rev Urol | 2005 | https://conductscience.org/library/papers/16985883 | PubMed |
| 15869726 | Preventing and treating the complications of hormone therapy. | Curr Urol Rep | 2005 | https://conductscience.org/library/papers/15869726 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11057778
GET https://conductscience.org/api/papers/v1/11057778/authors